Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan 160 mg vs 320 mg in Hypertension
NCT00241137Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2003
- Primary completion
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of valsartan in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline diastolic blood pressure at 4 weeks. Started Sep 2003; status: completed.
02
Drugs
valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00241137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241137.